ROCKVILLE, Md., Aug. 14, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three and six months ended June 30, 2013 and provided an operational update.
The Company's development portfolio includes three anti-infective product candidates, two of which are being developed in collaboration with Intrexon Corporation (NYSE: XON), and an oral multiple sclerosis (MS) product candidate in Phase II development. The relapsing-remitting MS clinical trial is expected to be completed in January 2014, with key data to be released shortly thereafter.Conference call scheduled for 4:00pm EDT today. To participate, please call1-800-860-2442 (U.S. toll free), 1-866-605-3852 (Canada), or +1 412-858-4600 (International),fifteen minutes before the start of the call to register. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=95523. "Our lead anti-infective candidate SYN-004 for the prevention of C. difficile (C. diff) infections, is a second generation compound designed to address a broader population than its predecessor, which successfully completed a proof-of-concept Phase II study in Europe," said Jeffrey Riley, Synthetic Biologics' CEO. "Manufacturing of SYN-004 is underway, and with completion of that we will be able to commence toxicology bridging studies, followed by the start of clinical trials in 2014."
"In addition, we are making excellent progress in our collaboration with Intrexon for antibody programs, which currently covers treatment candidates for Pertussis and Acinetobacter infections. We expect to initiate IND-enab
|SOURCE Synthetic Biologics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved